President Donald J. Trump’s endorsement of antimalarial hydroxychloroquine to treat COVID-19 has sent demand for the drug skyrocketing. But a tussle with India, a major U.S. drug supplier, over an export ban┬áhas added new concerns about the role of state actors in the global supply chain.